Neon Therapeutics, Translate Bio Join the Ranks of IPO Hopefuls
Xconomy Boston —
At this rate, 2018 could be a record-breaking year for biotech IPOs. Two more Boston-area companies filed their IPO plans late last week. Neon Therapeutics is developing personalized cancer vaccines, one of which is in Phase 1 clinical testing. Translate Bio is a messenger RNA (mRNA) company that started human testing just last month.
Neon and Translate each set a preliminary $115 million target for their respective IPOs, but that number is likely to change after the companies set their share price. Cambridge, MA-based Neon plans to list on the Nasdaq under the symbol “NTGN.” Translate, headquartered in Lexington, MA, has applied for a Nasdaq listing under the symbol “TBIO.”
Read more: https://www.xconomy.com/boston/2018/06/04/neon-therapeutics-translate-bio-join-the-ranks-of-ipo-hopefuls/
At this rate, 2018 could be a record-breaking year for biotech IPOs. Two more Boston-area companies filed their IPO plans late last week. Neon Therapeutics is developing personalized cancer vaccines, one of which is in Phase 1 clinical testing. Translate Bio is a messenger RNA (mRNA) company that started human testing just last month.
Neon and Translate each set a preliminary $115 million target for their respective IPOs, but that number is likely to change after the companies set their share price. Cambridge, MA-based Neon plans to list on the Nasdaq under the symbol “NTGN.” Translate, headquartered in Lexington, MA, has applied for a Nasdaq listing under the symbol “TBIO.”
Read more: https://www.xconomy.com/boston/2018/06/04/neon-therapeutics-translate-bio-join-the-ranks-of-ipo-hopefuls/